Obstructive sleep apnea syndrome (OSAS) is a serious, prevalent condition that has significant mortality and morbidity when untreated. It is strongly associated with obesity and is characterized by changes in the serum levels or secretory patterns of several hormones. In particular, obese patients with OSAS show a peculiar reduction of both spontaneous and stimulated growth hormone (GH) secretion coupled to reduced insulin-like growth factor-I (IGF-I) concentrations and impaired peripheral sensitivity to GH. These endocrine abnormalities are more marked than those observed in nonapneic obese subjects, and are likely to be due to the effects of hypoxia and sleep fragmentation on hormone secretory pattern. The GH/IGF-I axis activity disruption can be responsible, at least in part, for metabolic alterations, which are common in OSAS and increase the risk of cardiovascular events as well as mortality. Effective assessment and management of OSAS may correct endocrine changes, improve quality of life, and prevent associated morbidity or death.

Growth hormone/Insulin-like growth factor-I axis in obstructive sleep apnea sindrome: an update

LANFRANCO, Fabio;Motta G;MINETTO, Marco Alessandro;GHIGO, Ezio;MACCARIO, Mauro
2010

Abstract

Obstructive sleep apnea syndrome (OSAS) is a serious, prevalent condition that has significant mortality and morbidity when untreated. It is strongly associated with obesity and is characterized by changes in the serum levels or secretory patterns of several hormones. In particular, obese patients with OSAS show a peculiar reduction of both spontaneous and stimulated growth hormone (GH) secretion coupled to reduced insulin-like growth factor-I (IGF-I) concentrations and impaired peripheral sensitivity to GH. These endocrine abnormalities are more marked than those observed in nonapneic obese subjects, and are likely to be due to the effects of hypoxia and sleep fragmentation on hormone secretory pattern. The GH/IGF-I axis activity disruption can be responsible, at least in part, for metabolic alterations, which are common in OSAS and increase the risk of cardiovascular events as well as mortality. Effective assessment and management of OSAS may correct endocrine changes, improve quality of life, and prevent associated morbidity or death.
33
3
192
196
Lanfranco F.; Motta G; Minetto MA; Ghigo E; Maccario M.
File in questo prodotto:
File Dimensione Formato  
Lanfranco review JEI 2010.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 142.96 kB
Formato Adobe PDF
142.96 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/73584
Citazioni
  • ???jsp.display-item.citation.pmc??? 14
  • Scopus 33
  • ???jsp.display-item.citation.isi??? 32
social impact